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comorbidities but the patterns vary considerably across patients. Although most 
diabetes guidelines address co-management of hypertension and 
hyperlipidemia, this MCC subgroup accounts for only one-fifth of patients. The 
development of evidence-based strategies to manage MCCs would help 
physicians and patients prioritize therapies and goals.  
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OBJECTIVES: To assess the clinical characteristics and economic burden of  
type-2 diabetes patients in the U.S. veteran population METHODS: A 
retrospective database analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with type-2 diabetes were identified 
using International Classification of Disease 9th Revision Clinical Modification 
(ICD-9-CM) diagnosis code 250.x0 or 250.x2. Comorbidities and other clinical 
conditions were examined for the 12-month baseline period. Health care 
resource utilization and costs were assessed for the 12-month follow-up period. 
Descriptive statistics were calculated as means ± standard deviation  
and percentages to measure comorbidities, laboratory results, costs, and 
utilization distribution within the sample. RESULTS: A total of 741,406 veterans 
were identified as diagnosed with Type 2 diabetes. Of these patients, 18.77%  
had glycated hemoglobin (HbA1c) test results ≥7% and 27.21% had abnormal 
serum creatinine results. 62.71% of patients were obese with a body mass index 
(BMI) of ≥30. The most common comorbidities were unspecified essential 
hypertension (21.62%), other and unspecified hyperlipidemia (6.75%) and post-
traumatic stress disorder (5.15%). After examining treatment within 60 days of 
disease identification, simvastatin was the most commonly prescribed 
medication (21.62%), followed by metformin hydrochloride (27.43%). Insulin was 
also among the top 10 treatments with 10.67% of patients prescribed this 
medication. The percentage of patients with follow-up outpatient visits was 
99.80%, which translated into $6,531 average outpatient costs. The percentages 
of inpatient (13.21%), emergency room (16.94%), physician office (99.76%) and 
pharmacy visits (90.33%) were also calculated for diabetes patients. 
CONCLUSIONS: Obesity may play an important role in patients' development of 
diabetes since two-thirds of studied patients were obese prior to disease 
identification. Hypertension may also be an associated risk factor that should be 
further evaluated.  
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OBJECTIVES: The ADA/EASD guidelines suggest the management and treatment 
of type 2 diabetes mellitus (T2DM) can be impacted by many factors such as age, 
comorbidities, hypoglycemia risk, and treatment adherence. Understanding  
how the T2DM disease burden differs across race/ethnic groups may aid  
in individualization of treatment. METHODS: Using data from the 2011 patient-
reported US National Health and Wellness Survey (NHWS), we characterized the 
T2DM population by profiling patients by race/ethnicity (White, African 
American [AA], Hispanic, or Other). NHWS results were stratified, then weighted 
and projected to reflect the demographic composition of the total adult 
population (based on Census data for gender, age, race/ethnicity, and 
educational attainment). RESULTS: Of the total 7,828 patients with T2DM, 75.8% 
were White, 11.4% were AA, 6.7% were Hispanic, and 6.1% were Other (includes 
Asian American and American Indian). The top 3 comorbidities per group  
were the same for the 3 predominant groups: hypertension (62% Whites, 64% 
AAs, 55% Hispanics), high cholesterol (66% Whites, 58% AAs, 57% Hispanics), and 
pain (55% Whites, 50% AAs, 51% Hispanics). However, significantly more Whites 
reported high cholesterol than AAs and Hispanics (P=0.002 and P=0.001, 
respectively). Sixty three to seventy nine percent of White, AA, and Hispanic 
patients with T2DM reported body mass index (BMI) ≥30 kg/m2; <10% of  
all patients reported BMI <25 kg/m2. Furthermore, Hispanics reported lower 
medication adherence than Whites (57.4% vs 65% adherent; P=0.008); adherence 
among AAs was 63%. Hypoglycemia was reported by 54% of Hispanics, 51%  
of Whites, and 49% of AAs. CONCLUSIONS: Understanding the characteristics of 
patients with T2DM by race/ethnicity can provide insights on the types  
of diabetes management challenges that different patient populations may  
face. These observations may encourage providers to engage minority 
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OBJECTIVES: For insulin-treated patients with type 2 diabetes mellitus (T2DM), 
disposable pen may facilitate insulin administration compared to traditional 
vial/syringe. This study compared real-world outcomes of insulin glargine (GLA) 
administered via disposable pen versus vial/syringe injections among Medicaid 
T2DM patients. METHODS: Using 2007-2010 claims data from the 
MarketScan®Medicaid database, this retrospective study examined 1-year follow-
up outcomes among adult T2DM patients who were insulin-naive and initiated 
GLA via disposable pen (Pen Initiators, PI) or vial/syringe (Vial Initiators, VI), or 
GLA users continuing vial/syringe (Vial Continuers, VC) or switching to 
disposable pen (Pen Switchers, PS). Propensity-score matching was used to 
control for differences in baseline characteristics between PI and VI cohorts, and 
PS and VC cohorts, with each pen user matched to ≤2 vial users. Endpoints 
included 1-year treatment persistence and adherence, hypoglycemia, and health 
care costs. RESULTS: There were 2594 matched patients from 7 states and 2 
managed care plans in the insulin-naive cohorts (PI: n=983, VI: n=1,611; mean 
age 56 years, 65% female) and 2237 matched patients in the insulin-experienced 
cohorts (PS: n=783, VC: n=1454; mean age 52 years, 66% female). Compared with 
their respective matched cohorts, pen cohorts were significantly more 
treatment-persistent (PI: 49.2% vs. VI: 40.8%; PS: 45.6% vs. VC: 36.7%; both 
P<0.001) for longer time (276 vs. 247 and 257 vs. 236 days; both P<0.001). Similar 
numbers of patients had hypoglycemia among the insulin-naive (P=0.153) and 
insulin-experienced cohorts (P=0.164). Although pen users had significantly 
higher study drug costs than vial users (P<0.001), total health care costs were 
comparable (PI: $15,151 vs. VI: $15,994; P=0.458, and PS: $22,441 vs. VC: $22,403; 
P=0.984) due to an offset of medical costs. CONCLUSIONS: This real-world study 
suggests that, among Medicaid T2DM patients treated with GLA, use of 
disposable pen provides a beneficial effect of achieving better persistence 
without increasing overall health care costs.  
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OBJECTIVES: Patients with type-1 diabetes (T1D) can either use multiple daily 
injections or insulin pump therapy (IPT) to achieve glycemic control. However, 
there is a lack of real-world data on the differences in these treatment options, 
particularly as they relate to effectiveness. The objective of this study was to 
investigate the relationship between IPT and HbA1c among patients with T1D. 
METHODS: Data from unique respondents from the 2009-2012 U.S. National 
Health and Wellness Surveys were used. Among respondents who reported a 
diagnosis of T1D and reported using insulin, those who reported using IPT were 
compared with those who were not using IPT on reported HbA1c levels using an 
ordered logistic regression model controlling for sociodemographic and health 
history differences. RESULTS: A total of 1833 patients reported being diagnosed 
with T1D and were currently using insulin. Of these patients, 495 reported using 
IPT (27.0%). Patients using IPT had been diagnosed with T1D for longer (26.8 vs. 
21.1 years) and were significantly more likely to be female (53.1% vs. 42.5%), be 
non-Hispanic white (85.9% vs. 68.3%), have an annual household income of $75K 
or more (28.3% vs. 19.2%), and possess health insurance (95.8% vs. 84.5%) (all 
p<.05). Patients using IPT also reported significantly lower levels of HbA1c (7.2% 
vs. 7.5%, p<.05). Adjusting for sociodemographic and health history differences, 
patients using IPT were significantly less likely to report HbA1c levels 9% or more 
(b=-0.80, OR=0.45, p<.05). CONCLUSIONS: Although T1D patients with greater 
health care access were more likely to use IPT, even after adjusting for these 
differences, a significant effect of IPT was observed on HbA1c. These results 
suggest that IPT may be associated with greater real-world effectiveness, though 
additional research is necessary.  
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OBJECTIVES: To perform a meta-analysis of the clinical and biochemical 
outcomes of N-Acetyl Cysteine (NAC) in women with polycystic ovary syndrome 
(PCOS). METHODS: Systematic review of pertinent studies was conducted by 
using bibliographic databases such as MEDLINE (Ovid), CENTRAL, EMBASE and 
PsycInfo(inception to Nov 2012). References of selected articles were either hand-
searched and by using PROQUEST and Web of Science. The review included 
randomised controlled trials with women participants having PCOS and 
undergoing treatment with NAC alone or in combination with ovulation 
induction methods like clomiphene citrate (CC) or gonadotropin injections, or in 
vitro fertilization (IVF). RESULTS: Out of 182 retrieved reports, eight studies (900 
women) were included. Three studies compared NAC (n=179) to metformin 
(n=177) while five studies compared NAC (n=272) to placebo (n=269). Compared 
to placebo, NAC improved pregnancy rate (pooled odds ratio, OR: 3.97, 95%  
CI: 2.07, 7.59, 3 trials, 377 women, P<0.0001; I2: 53%), ovulation rate (OR: 4.49, 95% 
CI: 2.86, 7.04, 3 trials, 353 women, P<0.0001; I2: 85%) and live birth rate (OR: 3, 95% 
CI: 1.05, 8.60, 1 trial, 60 women, P=0.04). However, compared to metformin, NAC 
did not improve pregnancy rate, resumption of menstruation cycle, body mass 
index or testosterone level. NAC was signifianctly associated with lower 
ovulation rate (OR: 0.13, 95% CI: 0.08, 0.22, 2 trials, 253 women, P<0.0001; I2: 0%) 
compared to metformin. On the other hand, compared to NAC, metformin 
improved glucose and insulin resistance profiles. Also, when used alone or in 
combination with clomiphene, NAC did not significantly improve the 
anthropometric characteristics, testosterone levels, and lipid profiles compared 
to placebo and metformin. CONCLUSIONS: NAC was associated with improved 
clinical pregnancy but there was limited evidence that NAC improved live birth 
rates alone or in combination with clomiphene. Given the quality of studies, 
